Stephen Brady, Tempest Therapeutics CEO

Tem­pest Ther­a­peu­tics’ triple com­bo shows promise in first-line liv­er can­cer, stock jumps

Tem­pest Ther­a­peu­tics said Fri­day morn­ing that its ex­per­i­men­tal liv­er can­cer ther­a­py on top of stan­dard-of-care treat­ments helped shrink tu­mors in more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.